The Food and Drug Administration in the US has delayed granting approval for a new class of anti-diabetic medication- the SGLT2 inhibitor Dapagliflozin. The advisory committee cited a possible increased risk of bladder and breast cancers and of liver injury. The FDA are being very careful due the Avandia affair. Will we ever see this in the market? I am not very hopeful.